PLN 3.2
(-0.31%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -0.39 PLN | -745.99% |
2022 | -0.05 PLN | 92.8% |
2021 | -0.64 PLN | -100.0% |
2020 | -0.32 PLN | -190.91% |
2019 | -0.11 PLN | 38.89% |
2018 | -0.18 PLN | -12.5% |
2017 | -0.16 PLN | -142.42% |
2016 | -0.07 PLN | 85.96% |
2015 | -0.47 PLN | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -0.06 PLN | 15.05% |
2024 Q1 | -0.07 PLN | 65.37% |
2023 Q3 | -0.07 PLN | -6.78% |
2023 Q1 | -0.11 PLN | -161.11% |
2023 Q2 | -0.07 PLN | 38.36% |
2023 FY | - PLN | -767.68% |
2023 Q4 | -0.19 PLN | -162.43% |
2022 Q2 | -0.05 PLN | 73.9% |
2022 FY | - PLN | 92.8% |
2022 Q4 | 0.18 PLN | 326.99% |
2022 Q3 | -0.08 PLN | -51.92% |
2022 Q1 | -0.20 PLN | 51.22% |
2021 Q1 | -0.06 PLN | 73.96% |
2021 Q2 | -0.09 PLN | -49.42% |
2021 FY | - PLN | -100.0% |
2021 Q3 | -0.07 PLN | 19.89% |
2021 Q4 | -0.41 PLN | -471.83% |
2020 Q2 | -0.02 PLN | 27.83% |
2020 Q1 | -0.03 PLN | 48.41% |
2020 FY | - PLN | -190.91% |
2020 Q4 | -0.23 PLN | -2887.01% |
2020 Q3 | -0.01 PLN | 65.47% |
2019 Q2 | -0.03 PLN | -189.47% |
2019 Q1 | -0.01 PLN | 10.38% |
2019 FY | - PLN | 38.89% |
2019 Q3 | -0.01 PLN | 52.36% |
2019 Q4 | -0.06 PLN | -357.25% |
2018 Q2 | -0.06 PLN | 0.83% |
2018 Q3 | -0.04 PLN | 34.62% |
2018 FY | - PLN | -12.5% |
2018 Q4 | -0.01 PLN | 72.75% |
2018 Q1 | -0.06 PLN | -8.3% |
2017 Q2 | -0.03 PLN | 32.0% |
2017 FY | - PLN | -142.42% |
2017 Q3 | -0.03 PLN | -10.66% |
2017 Q1 | -0.04 PLN | 0.0% |
2017 Q4 | -0.06 PLN | -84.05% |
2016 FY | - PLN | 85.96% |
2015 FY | - PLN | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Bioceltix S.A. | -3.49 PLN | 88.825% |
BIOTON S.A. | 0.03 PLN | 1571.698% |
Captor Therapeutics Spolka Akcyjna | -15.19 PLN | 97.433% |
Mabion S.A. | 2.55 PLN | 115.294% |
Molecure S.A. | -1.09 PLN | 64.22% |
Pharmena S.A. | 2.60 PLN | 115.0% |
Poltreg S.A. | -2.91 PLN | 86.598% |
Pure Biologics Spólka Akcyjna | -11.19 PLN | 96.515% |
Ryvu Therapeutics S.A. | -4.02 PLN | 90.299% |
Synthaverse S.A. | 0.07 PLN | 676.071% |
Urteste S.A. | -4.32 PLN | 90.972% |